Merck & Co Inc (MRK)

62.14
NYSE : Health Care
Prev Close 62.14
Day Low/High 0.00 / 0.00
52 Wk Low/High 53.06 / 66.80
Avg Volume 9.19M
Exchange NYSE
Shares Outstanding 2.74B
Market Cap 169.67B
EPS 1.40
P/E Ratio 43.89
Div & Yield 1.88 (3.00%)

Latest News

Real-World Observational Study In The U.S. Veterans Affairs System Evaluating Use Of Merck's ZEPATIER® (Elbasvir And Grazoprevir) Shows High Sustained Virologic Response Rates In Patients With Chronic Hepatitis C

Real-World Observational Study In The U.S. Veterans Affairs System Evaluating Use Of Merck's ZEPATIER® (Elbasvir And Grazoprevir) Shows High Sustained Virologic Response Rates In Patients With Chronic Hepatitis C

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a retrospective database analysis of patients with chronic hepatitis C virus (HCV) infection who...

Merck Donates $300,000 To Support Neglected Tropical Disease Elimination Efforts In Africa

Merck Donates $300,000 To Support Neglected Tropical Disease Elimination Efforts In Africa

Merck, known as MSD outside the United States and Canada, announced today a $300,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic...

Merck Underscores Continued Commitment To Fighting Infectious Diseases With More Than 25 Data Presentations At ECCMID 2017

Merck Underscores Continued Commitment To Fighting Infectious Diseases With More Than 25 Data Presentations At ECCMID 2017

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 25 scientific data presentations on the company's established and investigational...

Togo Becomes First Country In Africa To Validate The Elimination Of Lymphatic Filariasis As A Public Health Problem

Togo Becomes First Country In Africa To Validate The Elimination Of Lymphatic Filariasis As A Public Health Problem

GSK, Merck Sharp & Dohme (MSD), and the MECTIZAN ® Donation Program (MDP) congratulate President Faure Gnassingbé, the government and the people of Togo for becoming the first country in Africa recognized by...

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Apple, Allergan and Western Digital.

Merck Becomes #26 Most Shorted Dow Stock, Replacing McDonald's

Merck Becomes #26 Most Shorted Dow Stock, Replacing McDonald's

The most recent short interest data has been released for the 03/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma

Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma

Eli Lilly has become the new go-to name in the pharmaceutical space, even over Johnson & Johnson, Cramer said.

Dr. John H. Noseworthy Nominated To Stand For Election To Merck Board Of Directors

Dr. John H. Noseworthy Nominated To Stand For Election To Merck Board Of Directors

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr.

Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments

Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments

'These companies are all assessing the Trump effect,' Cramer said.

Jim Cramer -- Incyte Stock Is Red-Hot, Worth More Than $200 in a Takeout

Jim Cramer -- Incyte Stock Is Red-Hot, Worth More Than $200 in a Takeout

Incyte has been doing great, locking in deals with Bristol-Myers and Merck. It's worth a lot more in a takeover situation, Cramer said.

Merck Receives Complete Response Letter From The U.S. FDA For TECOS Study With Sitagliptin

Merck Receives Complete Response Letter From The U.S. FDA For TECOS Study With Sitagliptin

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Merck Receives 2017 ENERGY STAR Sustained Excellence Award From U. S. Environmental Protection Agency

Merck Receives 2017 ENERGY STAR Sustained Excellence Award From U. S. Environmental Protection Agency

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has received an ENERGY STAR 2017 Partner of the Year - Sustained Excellence Award from the U.

Merck To Present New Data On ZEPATIER® (elbasvir And Grazoprevir) And Investigational Combination Therapy MK-3682B For The Treatment Of Chronic Hepatitis C Infection At The International Liver Congress™ 2017

Merck To Present New Data On ZEPATIER® (elbasvir And Grazoprevir) And Investigational Combination Therapy MK-3682B For The Treatment Of Chronic Hepatitis C Infection At The International Liver Congress™ 2017

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company's chronic hepatitis C virus (HCV) clinical development programs as well as real-world studies on...

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

As Biotech Roars Back, Amgen Remains Dirt Cheap

As Biotech Roars Back, Amgen Remains Dirt Cheap

The biotechnology sector is enjoying robust recovery, driving Big Pharma shares to lofty levels. But this biotech stalwart is a great value play now.

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.

Cramer: Stay the Course, but Keep Cash Handy

Cramer: Stay the Course, but Keep Cash Handy

It's pretty normal to have profit-taking after such a strong first quarter.

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

The broad development plan across five different types of cancer widens Incyte's lead over other IDO inhibitors in clinical development.

Merck To Hold First-Quarter 2017 Sales And Earnings Conference Call On May 2

Merck To Hold First-Quarter 2017 Sales And Earnings Conference Call On May 2

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2017 sales and earnings conference call with institutional investors and analysts at 8:00 a.

Cramer: We Have Nothing to Distinguish the Stocks Right Now

Cramer: We Have Nothing to Distinguish the Stocks Right Now

We know that we are in the era when index managers are ascendant.

3 Reasons Why Merck Is No Match for Dividend King Johnson & Johnson

3 Reasons Why Merck Is No Match for Dividend King Johnson & Johnson

Johnson & Johnson is the better investment today versus Merck.

Austin to be Location of Merck IT Hub

Austin to be Location of Merck IT Hub

The hub is expected to house 600 jobs.

Incyte And Merck Provide Additional Details On Previously Announced Collaboration Investigating Epacadostat And KEYTRUDA® (pembrolizumab)

Incyte And Merck Provide Additional Details On Previously Announced Collaboration Investigating Epacadostat And KEYTRUDA® (pembrolizumab)

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of...

VBI Vaccines Emerges as Strong Biotech Stock

VBI Vaccines Emerges as Strong Biotech Stock

Armed with an arsenal of vaccines in its product pipeline, this small biotech company is ready to rocket.

Week Ahead: Financials, Health Care on Edge as Obamacare Escapes GOP Axe

Week Ahead: Financials, Health Care on Edge as Obamacare Escapes GOP Axe

Wall Street could be in for a rocky week in the wake of the Republicans' failure to repeal and replace Obamacare as promised.

Trump, Ryan Spike Health Care Vote in Setback for President, GOP

Trump, Ryan Spike Health Care Vote in Setback for President, GOP

The vote on repealing and replacing Obamacare has been pulled from the House floor.

Merck Is Dangerously Close to a Breakdown

Merck Is Dangerously Close to a Breakdown

Merck is struggling to attract buyers as it tests a key support area.

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.